SB525334
Suppliers
Names
[ CAS No. ]:
356559-20-1
[ Name ]:
SB525334
[Synonym ]:
6-[2-tert-Butyl-4-(6-methylpyridin-2-yl)-1H-imidazol-5-yl]quinoxaline
6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline
SB 525334
Quinoxaline, 6-[2-(1,1-dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]-
6-[2-(2-Methyl-2-propanyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline
6-(2-tert-butyl-4-(6-methylpyridin-2-yl)-1H-imidazol-5-yl)quinoxaline
S1476_Selleck
SB525334
6-(2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline
6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline
Chemical & Physical Properties
[ Density]:
1.2±0.1 g/cm3
[ Boiling Point ]:
540.5±45.0 °C at 760 mmHg
[ Melting Point ]:
159 °C
[ Molecular Formula ]:
C21H21N5
[ Molecular Weight ]:
343.425
[ Flash Point ]:
238.6±21.7 °C
[ Exact Mass ]:
343.179688
[ PSA ]:
67.35000
[ LogP ]:
4.05
[ Appearance of Characters ]:
yellow
[ Vapour Pressure ]:
0.0±1.4 mmHg at 25°C
[ Index of Refraction ]:
1.636
[ Storage condition ]:
2-8°C
[ Water Solubility ]:
DMSO: ≥20mg/mL
MSDS
Safety Information
[ Symbol ]:
GHS06
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301-H315-H319-H335-H413
[ Precautionary Statements ]:
P261-P301 + P310-P305 + P351 + P338
[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves
[ Hazard Codes ]:
Xn
[ Risk Phrases ]:
22-36/37/38
[ Safety Phrases ]:
26
[ RIDADR ]:
UN 2811 6.1/PG 3
[ Hazard Class ]:
6.1
[ HS Code ]:
2934999090
Customs
[ HS Code ]: 2934999090
[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Articles
Endocrinology 152 , 5017-28, (2011)
Placental development is markedly abnormal in trisomy 21 (T21) pregnancies. We hypothesized that abnormal paracrine cross talk between the fetal mesenchymal core and the trophoblast might be involved ...
J. Pharmacol. Exp. Ther. 313 , 943-951, (2005)
SB-525334 (6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline) has been characterized as a potent and selective inhibitor of the transforming growth factor-beta1 (TGF-beta1) recep...
Am. J. Pathol. 174(2) , 380-9, (2009)
Mutations in the gene for the transforming growth factor (TGF)-β superfamily receptor, bone morphogenetic protein receptor II, underlie heritable forms of pulmonary arterial hypertension (PAH). Aberra...